<DOC>
	<DOCNO>NCT00613171</DOCNO>
	<brief_summary>This study investigate efficacy safety STI571 treatment fibrosis patient systemic sclerosis . Other purpose study investigate whether STI571 effective improving lung function test result call biomarkers . Whether STI571 well-absorbed systemic sclerosis patient ' gut also investigate test drug level blood ( pharmacokinetics ) .</brief_summary>
	<brief_title>Efficacy Tolerability STI571 ( Imatinib Mesylate ) Treatment Fibrosis Patients With Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Male female patient equal old 18 year age early diffuse systemic sclerosis ( Disease duration &lt; 18 month first nonRaynaud 's symptom ) Patients modified Rodnans Skin Score ( MRSS ) least 20 absence trunk involvement MRSS least 16 patient trunk involvement Practicing two acceptable form contraception Concurrent connective tissue disease systemic sclerosis Significant preexist heart , liver , lung , digestive system , blood disease , cancer Conditions might mimic potential side effect STI571 ( blood condition , liver damage , chronic diarrhea , edema ) Concurrent medical therapy ( last 6 week first dose ) may potentially influence outcome study allergic study medication Pregnancy Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Systemic sclerosis , scleroderma , fibrosis , STI571 , imatinib</keyword>
</DOC>